Company profile

RIGEL PHARMACEUTICALS INC

NASDAQ:RIGLBiotechnology: Pharmaceutical Preparations

Drug pipeline (5)

AssetStageRevenueTrialsStatus
FOSTAMATINIB DISODIUMapproved11approved
OLUTASIDENIBapproved2approved
Pralsetinibapproved1approved
Vepdegestrantapproved9approved
R-343phase21no active trials

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (26)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT00115089phase2completed2005-07-01Rigel Pharmaceuticals7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis
NCT02076412phase3completed2015-01-012016-08-01Rigel PharmaceuticalsA Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
NCT02076399phase3completed2014-07-142016-04-21Rigel PharmaceuticalsA Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
NCT04138927phase3enrolling_by_invitation2019-10-302024-04-01Rigel PharmaceuticalsA Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
NCT03764618phase3completed2019-04-242022-04-11Rigel PharmaceuticalsA Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA

FDA applications (4)

ApplicationTypeApplicantProducts
NDA 209299NDARIGEL PHARMACEUTICALS INC
NDA 213721NDARIGEL PHARMACEUTICALS INC
NDA 215814NDARIGEL PHARMACEUTICALS INC
NDA 219835NDARIGEL PHARMACEUTICALS INC